Westin J, Cortelezzi A, Hjorth M, Rödjer S, Turesson I, Zador G
Department of Medicine, University Hospital, Lund, Sweden.
Eur J Cancer. 1991;27 Suppl 4:S45-8. doi: 10.1016/0277-5379(91)90571-t.
A multicentre clinical trial was carried out in order to evaluate the effect of interferon (IFN) in patients with multiple myeloma. Patients (n = 120) who had shown response to conventional intermittent melphalan-prednisone induction therapy, and achieved a plateau phase, were randomized at that point to receive either interferon alfa-2b in a dose of 5 million units (MU) three times per week or no therapy. This report presents the results of an interim analysis, performed when the patients had been followed for a median of 20 months. The duration of the plateau phase was significantly longer in the IFN arm (59 weeks), compared to the no therapy arm (26 weeks). A total of 34 deaths have occurred, 13 in the IFN arm and 21 in the no therapy arm. In spite of the high median age of the patients studied (70 years), most patients were able to tolerate a full or only slightly reduced IFN dose.
为了评估干扰素（IFN）对多发性骨髓瘤患者的疗效，开展了一项多中心临床试验。对传统间歇性美法仑-泼尼松诱导疗法有反应且进入平台期的患者（n = 120），在此时被随机分组，分别接受每周三次、剂量为500万单位（MU）的α-2b干扰素治疗或不接受治疗。本报告呈现了一项中期分析的结果，该分析在患者中位随访20个月时进行。与未治疗组（26周）相比，干扰素治疗组的平台期持续时间显著更长（59周）。总共发生了34例死亡，其中干扰素治疗组13例，未治疗组21例。尽管所研究患者的中位年龄较高（70岁），但大多数患者能够耐受全剂量或仅略微减量的干扰素治疗。
